Markets:

Overview

News

Currencies

International

Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

109.44 +5.24 (+5.03%)

Streaming Delayed Price Updated: 2:38 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers

June 03, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and...

Via StockStory

3 of Wall Street’s Favorite Stocks in Hot Water

June 02, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know

May 12, 2025

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...

Via StockStory

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

The Analyst Verdict: Repligen In The Eyes Of 4 Experts ↗

February 21, 2025

Via Benzinga

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Evaluating Repligen: Insights From 6 Financial Analysts ↗

September 26, 2024

Via Benzinga

1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar

May 09, 2025

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,...

Via StockStory

Deep Dive Into Repligen Stock: Analyst Perspectives (8 Ratings) ↗

April 30, 2025

Via Benzinga

RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty

April 30, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 10.4% year on year to $169.2 million. The company’s...

Via StockStory

Topics World Trade

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

April 29, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.4% year on year to $169.2 million. The...

Via StockStory

Topics World Trade

Repligen (RGEN) Q1 Earnings: What To Expect

April 28, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for.

Via StockStory

Topics World Trade

3 Healthcare Stocks That Concern Us

April 25, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...

Via StockStory

Topics Stocks

Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

April 10, 2025

Repligen trades at $120.32 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 10.5% while the S&P 500 is down 7.7%. This might have investors...

Via StockStory

Topics Stocks

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

March 26, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest...

Via StockStory

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

March 21, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.

Via StockStory

Demystifying Repligen: Insights From 6 Analyst Reviews ↗

March 18, 2025

Via Benzinga

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

March 17, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.

Via StockStory

Topics Artificial Intelligence

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

March 12, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers.

Via StockStory

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

March 11, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and...

Via StockStory

3 Small-Cap Stocks Skating on Thin Ice

March 06, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth ↗

March 04, 2025

Repligen acquires 908 Devices' desktop portfolio for $70 million, enhancing its bioprocessing analytics. 908 Devices shifts focus to handheld growth, forecasting revenue gains.

Via Benzinga

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook ↗

February 20, 2025

Repligen reported Q4 EPS of $0.44, beating estimates, with revenue of $167.55 million. The company projects 2025 sales of up to $710 million as the market recovers.

Via Benzinga

Repligen's Q4 Slightly Tops Expectations ↗

February 20, 2025

The bioprocessing technology specialist's fourth-quarter results were dragged down by restructuring costs.

Via The Motley Fool

Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

February 20, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the...

Via StockStory

Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow

February 19, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know.

Via StockStory

3 Healthcare Stocks Skating on Thin Ice

February 12, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But near-term speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and...

Via StockStory

Topics Stocks

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth ↗

November 12, 2024

Repligen Q3 earnings beat expectations with $0.43 EPS and $154.87 million in sales. The company raises 2024 EPS guidance and reports strong growth in CDMO and equipment.

Via Benzinga

Topics Earnings

10 Health Care Stocks Whale Activity In Today's Session ↗

November 12, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Repligen Corporation - Common Stock (NQ:RGEN)

All News about Repligen Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today